Which of the following is a limitation on the use of Ex Vivo gene therapy for genetic diseases? A. Our ability to inject an AAV into cells of the diseased tissue B. In Ex Vivo gene therapy you have more opportunity to screen for successful transformation of cells C. Ex Vivo gene therapy is approved for use in a suite of blood associated genetic diseases D. Our ability to harvest and grow stem cells that, if modified, can treat the condition